Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)

@inproceedings{Petrausch2012RedirectedTC,
  title={Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)},
  author={Ulf Petrausch and Petra C. Schuberth and Christian Hagedorn and Alex Soltermann and Sandra C. Tomaszek and Rolf Arno Stahel and Walter Weder and Christoph Renner},
  booktitle={BMC Cancer},
  year={2012}
}
Asbestos is the main cause of MPM in industrialized countries. Even since asbestos is banned in most developed countries, the peak wave of MPM incidence is anticipated for the next years due to the long latency of asbestos induced MPM. MPM patients not eligible for surgical procedures like decortication or pleuro-pneumectomie have a median survival of 12 months with palliative chemotherapy. Therefore, new therapeutic approaches are of crucial need in this clinical situation. This is a phase I… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

  • CH Lamers, R Willemsen, +7 authors JW Gratama
  • Blood
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…